ACTU (Actuate Therapeutics) ROE % Adjusted to Book Value: -22.44% (As of Mar. 2026)


ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.82
View Full Analysis

What is Actuate Therapeutics ROE % Adjusted to Book Value?

Actuate Therapeutics ACTU -14.29% 14 ROE % Adjusted to Book Value is -22.44% as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Actuate Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -384.42%. Actuate Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 17.13. Actuate Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -22.44%.

Actuate Therapeutics ROE % Adjusted to Book Value Related Terms

Actuate Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics ROE % Adjusted to Book Value Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 -30.85

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -36.78 -10.76 -22.44

ACTU vs AURX, ESLA, MGX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Actuate Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's ROE % Adjusted to Book Value falls into.


ACTU
14GF Score
Actuate Therapeutics Inc ACTU
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics ROE % Adjusted to Book Value Calculation

Actuate Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-553.76% / 17.95
=-30.85%

Actuate Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-384.42% / 17.13
=-22.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -22.44% mean?
Actuate Therapeutics (ACTU) has a ROE % Adjusted to Book Value of -22.44% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' ROE % Adjusted to Book Value too high?
Actuate Therapeutics' current ROE % Adjusted to Book Value is -22.44%. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' ROE % Adjusted to Book Value compare to AURX and ESLA?
Actuate Therapeutics' ROE % Adjusted to Book Value of -22.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current ROE % Adjusted to Book Value is -22.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current ROE % Adjusted to Book Value of -22.44%. The current ROE % Adjusted to Book Value is -22.44%. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current ROE % Adjusted to Book Value is -22.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.82
Price